Home/Filings/4/0001209191-22-058154
4//SEC Filing

KANNAN RAJ 4

Accession 0001209191-22-058154

CIK 0001337553other

Filed

Nov 20, 7:00 PM ET

Accepted

Nov 21, 4:30 PM ET

Size

10.5 KB

Accession

0001209191-22-058154

Insider Transaction Report

Form 4
Period: 2022-11-21
KANNAN RAJ
DirectorChief Executive Officer
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-11-21$7.14/sh387,169$2,764,3870 total
    Exercise: $8.11Exp: 2031-12-20Common Stock (387,169 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-11-21$6.45/sh197,239$1,272,1920 total
    Exercise: $8.80Exp: 2032-03-18Common Stock (197,239 underlying)
  • Disposition to Issuer

    Common Stock

    2022-11-21$15.25/sh215,783$3,290,6910 total
Footnotes (2)
  • [F1]Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.
  • [F2]Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.

Issuer

AERIE PHARMACEUTICALS INC

CIK 0001337553

Entity typeother

Related Parties

1
  • filerCIK 0001778539

Filing Metadata

Form type
4
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 4:30 PM ET
Size
10.5 KB